Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 18/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471552 | 0.82 | TGFBR1 (0.52) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL4833839 | 0.82 | KMT2A (0.46) | THRBTGFBR1MAPK14KDM4E | |
| SCHEMBL3944343 | 0.80 | TGFBR1 (0.61) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL14108193 | 0.78 | THRB (0.61) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL3944132 | 0.78 | THRB (0.61) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL13932934 | 0.77 | TGFBR1 (0.58) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL3941021 | 0.77 | THRB (0.57) | THRBTGFBR1MAPK14TGFBR2MAP3K20 | |
| SCHEMBL2522496 | 0.76 | CSNK1D (0.47) | THRBTGFBR1MAPK14KDM4E | |
| SCHEMBL3359415 | 0.74 | TGFBR1 (0.82) | THRBTGFBR1MAPK14 | |
| SCHEMBL409222 | 0.74 | TGFBR1 (0.73) | THRBTGFBR1MAPK14TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1723146-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006052568-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006005741-A2 | PIPERDINE DERIVATIVES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005092894-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | THRB 318/4885TGFBR1 3/4885MAPK14 199/4885 |
| US-20080262004-A1 | Tgf-Beta Inhibitors | TGFB1, TGFBR1, TGFB2 | THRB 108/4885TGFBR1 2/4885MAPK14 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.